Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.
2.

Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.

Fawaz MV, Kim SY, Li D, Ming R, Xia Z, Olsen K, Pogozheva ID, Tesmer JJG, Schwendeman A.

J Pharmacol Exp Ther. 2020 Feb;372(2):193-204. doi: 10.1124/jpet.119.257568. Epub 2019 Nov 27.

PMID:
31776208
3.

TMPfold: A Web Tool for Predicting Stability of Transmembrane α-Helix Association.

Lomize AL, Schnitzer KA, Pogozheva ID.

J Mol Biol. 2019 Nov 1. pii: S0022-2836(19)30620-5. doi: 10.1016/j.jmb.2019.10.024. [Epub ahead of print]

PMID:
31682836
4.

Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules.

Lomize AL, Pogozheva ID.

J Chem Inf Model. 2019 Jul 22;59(7):3198-3213. doi: 10.1021/acs.jcim.9b00224. Epub 2019 Jul 1.

5.

PerMM: A Web Tool and Database for Analysis of Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules.

Lomize AL, Hage JM, Schnitzer K, Golobokov K, LaFaive MB, Forsyth AC, Pogozheva ID.

J Chem Inf Model. 2019 Jul 22;59(7):3094-3099. doi: 10.1021/acs.jcim.9b00225. Epub 2019 Jul 1.

6.

Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show in Vitro Kappa and Mu Opioid Receptor Agonism.

Montgomery D, Anand JP, Griggs NW, Fernandez TJ, Hartman JG, Sánchez-Santiago AA, Pogozheva ID, Traynor JR, Mosberg HI.

ACS Chem Neurosci. 2019 Aug 21;10(8):3682-3689. doi: 10.1021/acschemneuro.9b00250. Epub 2019 Jul 1.

7.

Effect of Site-Specific Intermolecular Lysine-Tryptophan Interactions on the Aggregation of Gramicidin-Based Peptides Leading to Pore Formation in Lipid Membranes.

Firsov AM, Pogozheva ID, Kovalchuk SI, Kotova EA, Antonenko YN.

J Membr Biol. 2018 Dec;251(5-6):633-640. doi: 10.1007/s00232-018-0040-0. Epub 2018 Jul 11.

PMID:
29995247
8.

Evolution and adaptation of single-pass transmembrane proteins.

Pogozheva ID, Lomize AL.

Biochim Biophys Acta Biomembr. 2018 Feb;1860(2):364-377. doi: 10.1016/j.bbamem.2017.11.002. Epub 2017 Nov 10.

9.

Membranome 2.0: database for proteome-wide profiling of bitopic proteins and their dimers.

Lomize AL, Hage JM, Pogozheva ID.

Bioinformatics. 2018 Mar 15;34(6):1061-1062. doi: 10.1093/bioinformatics/btx720.

PMID:
29126305
10.

Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.

Harland AA, Pogozheva ID, Griggs NW, Trask TJ, Traynor JR, Mosberg HI.

ACS Chem Neurosci. 2017 Nov 15;8(11):2549-2557. doi: 10.1021/acschemneuro.7b00284. Epub 2017 Aug 25.

11.

TMDOCK: An Energy-Based Method for Modeling α-Helical Dimers in Membranes.

Lomize AL, Pogozheva ID.

J Mol Biol. 2017 Feb 3;429(3):390-398. doi: 10.1016/j.jmb.2016.09.005. Epub 2016 Sep 10.

PMID:
27622289
12.

Membranome: a database for proteome-wide analysis of single-pass membrane proteins.

Lomize AL, Lomize MA, Krolicki SR, Pogozheva ID.

Nucleic Acids Res. 2017 Jan 4;45(D1):D250-D255. doi: 10.1093/nar/gkw712. Epub 2016 Aug 10.

13.

Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands.

Harland AA, Bender AM, Griggs NW, Gao C, Anand JP, Pogozheva ID, Traynor JR, Jutkiewicz EM, Mosberg HI.

J Med Chem. 2016 May 26;59(10):4985-98. doi: 10.1021/acs.jmedchem.6b00308. Epub 2016 May 16.

14.

Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.

Harland AA, Yeomans L, Griggs NW, Anand JP, Pogozheva ID, Jutkiewicz EM, Traynor JR, Mosberg HI.

J Med Chem. 2015 Nov 25;58(22):8952-69. doi: 10.1021/acs.jmedchem.5b01270. Epub 2015 Nov 13.

15.

Use of Functional Polymorphisms To Elucidate the Peptide Binding Site of TAP Complexes.

Geng J, Pogozheva ID, Mosberg HI, Raghavan M.

J Immunol. 2015 Oct 1;195(7):3436-48. doi: 10.4049/jimmunol.1500985. Epub 2015 Aug 31.

16.

Gramicidin A disassembles large conductive clusters of its lysine-substituted derivatives in lipid membranes.

Antonenko YN, Gluhov GS, Firsov AM, Pogozheva ID, Kovalchuk SI, Pechnikova EV, Kotova EA, Sokolova OS.

Phys Chem Chem Phys. 2015 Jul 14;17(26):17461-70. doi: 10.1039/c5cp02047f.

PMID:
26077982
17.

Life at the border: adaptation of proteins to anisotropic membrane environment.

Pogozheva ID, Mosberg HI, Lomize AL.

Protein Sci. 2014 Sep;23(9):1165-96. doi: 10.1002/pro.2508. Epub 2014 Jul 2. Review.

18.

Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Anand JP, Porter-Barrus VR, Waldschmidt HV, Yeomans L, Pogozheva ID, Traynor JR, Mosberg HI.

Biopolymers. 2014 Jan;102(1):107-14. doi: 10.1002/bip.22437. Erratum in: Biopolymers. 2014 Sep;102(5):426.

19.

Solvation models and computational prediction of orientations of peptides and proteins in membranes.

Lomize AL, Pogozheva ID.

Methods Mol Biol. 2013;1063:125-42. doi: 10.1007/978-1-62703-583-5_7.

PMID:
23975775
20.

Structural adaptations of proteins to different biological membranes.

Pogozheva ID, Tristram-Nagle S, Mosberg HI, Lomize AL.

Biochim Biophys Acta. 2013 Nov;1828(11):2592-608. doi: 10.1016/j.bbamem.2013.06.023. Epub 2013 Jun 27.

21.

Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.

Anand JP, Purington LC, Pogozheva ID, Traynor JR, Mosberg HI.

Chem Biol Drug Des. 2012 Nov;80(5):763-70. doi: 10.1111/cbdd.12014. Epub 2012 Sep 12.

22.

Rescue of misrouted GnRHR mutants reveals its constitutive activity.

Janovick JA, Pogozheva ID, Mosberg HI, Cornea A, Conn PM.

Mol Endocrinol. 2012 Jul;26(7):1179-88. doi: 10.1210/me.2012-1089. Epub 2012 May 17.

23.

Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Purington LC, Sobczyk-Kojiro K, Pogozheva ID, Traynor JR, Mosberg HI.

ACS Chem Biol. 2011 Dec 16;6(12):1375-81. doi: 10.1021/cb200263q. Epub 2011 Oct 11.

24.

OPM database and PPM web server: resources for positioning of proteins in membranes.

Lomize MA, Pogozheva ID, Joo H, Mosberg HI, Lomize AL.

Nucleic Acids Res. 2012 Jan;40(Database issue):D370-6. doi: 10.1093/nar/gkr703. Epub 2011 Sep 2.

25.

Membrane topology of the colicin E1 channel using genetically encoded fluorescence.

Ho D, Lugo MR, Lomize AL, Pogozheva ID, Singh SP, Schwan AL, Merrill AR.

Biochemistry. 2011 Jun 7;50(22):4830-42. doi: 10.1021/bi101934e. Epub 2011 May 11.

PMID:
21528912
26.

Salt bridges overlapping the gonadotropin-releasing hormone receptor agonist binding site reveal a coincidence detector for G protein-coupled receptor activation.

Janovick JA, Pogozheva ID, Mosberg HI, Conn PM.

J Pharmacol Exp Ther. 2011 Aug;338(2):430-42. doi: 10.1124/jpet.111.180869. Epub 2011 Apr 28.

27.

Anisotropic solvent model of the lipid bilayer. 1. Parameterization of long-range electrostatics and first solvation shell effects.

Lomize AL, Pogozheva ID, Mosberg HI.

J Chem Inf Model. 2011 Apr 25;51(4):918-29. doi: 10.1021/ci2000192. Epub 2011 Mar 25.

28.

Anisotropic solvent model of the lipid bilayer. 2. Energetics of insertion of small molecules, peptides, and proteins in membranes.

Lomize AL, Pogozheva ID, Mosberg HI.

J Chem Inf Model. 2011 Apr 25;51(4):930-46. doi: 10.1021/ci200020k. Epub 2011 Mar 25.

29.

Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity.

René P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS, Valenzano KJ, Bouvier M.

J Pharmacol Exp Ther. 2010 Dec;335(3):520-32. doi: 10.1124/jpet.110.172098. Epub 2010 Sep 8.

PMID:
20826565
30.

Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Purington LC, Pogozheva ID, Traynor JR, Mosberg HI.

J Med Chem. 2009 Dec 10;52(23):7724-31. doi: 10.1021/jm9007483.

31.

Discovery of a ligand that compensates for decreased endogenous agonist potency of melanocortin-4 receptor polymorphisms identified in obese humans.

Haskell-Luevano C, Xiang Z, Wilczynski AM, Haskell KR, Andreasen AM, Litherland SA, Millard WJ, Pogozheva ID, Mosberg HI, Sorenson NB.

Adv Exp Med Biol. 2009;611:509-10. No abstract available.

PMID:
19400288
32.

Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor.

Tan K, Pogozheva ID, Yeo GS, Hadaschik D, Keogh JM, Haskell-Leuvano C, O'Rahilly S, Mosberg HI, Farooqi IS.

Endocrinology. 2009 Jan;150(1):114-25. doi: 10.1210/en.2008-0721. Epub 2008 Sep 18.

33.
34.

Novel peptide ligands of RGS4 from a focused one-bead, one-compound library.

Roof RA, Sobczyk-Kojiro K, Turbiak AJ, Roman DL, Pogozheva ID, Blazer LL, Neubig RR, Mosberg HI.

Chem Biol Drug Des. 2008 Aug;72(2):111-9. doi: 10.1111/j.1747-0285.2008.00687.x. Epub 2008 Jul 15.

35.

The role of hydrophobic interactions in positioning of peripheral proteins in membranes.

Lomize AL, Pogozheva ID, Lomize MA, Mosberg HI.

BMC Struct Biol. 2007 Jun 29;7:44.

36.

Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms.

Xiang Z, Pogozheva ID, Sorenson NB, Wilczynski AM, Holder JR, Litherland SA, Millard WJ, Mosberg HI, Haskell-Luevano C.

Biochemistry. 2007 Jul 17;46(28):8273-87. Epub 2007 Jun 23.

PMID:
17590021
37.

Positioning of proteins in membranes: a computational approach.

Lomize AL, Pogozheva ID, Lomize MA, Mosberg HI.

Protein Sci. 2006 Jun;15(6):1318-33.

38.

Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism.

Proneth B, Xiang Z, Pogozheva ID, Litherland SA, Gorbatyuk OS, Shaw AM, Millard WJ, Mosberg HI, Haskell-Luevano C.

Chem Biol Drug Des. 2006 Mar;67(3):215-29.

39.

OPM: orientations of proteins in membranes database.

Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI.

Bioinformatics. 2006 Mar 1;22(5):623-5. Epub 2006 Jan 5.

PMID:
16397007
40.

Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Pogozheva ID, Przydzial MJ, Mosberg HI.

AAPS J. 2005 Oct 5;7(2):E434-48. Review.

41.

Exploring the active site of benzaldehyde lyase by modeling and mutagenesis.

Kneen MM, Pogozheva ID, Kenyon GL, McLeish MJ.

Biochim Biophys Acta. 2005 Dec 1;1753(2):263-71. Epub 2005 Sep 29.

PMID:
16226928
42.

Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.

Przydzial MJ, Pogozheva ID, Ho JC, Bosse KE, Sawyer E, Traynor JR, Mosberg HI.

J Pept Res. 2005 Nov;66(5):255-62.

43.

Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Pogozheva ID, Chai BX, Lomize AL, Fong TM, Weinberg DH, Nargund RP, Mulholland MW, Gantz I, Mosberg HI.

Biochemistry. 2005 Aug 30;44(34):11329-41.

44.

Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.

Przydzial MJ, Pogozheva ID, Bosse KE, Andrews SM, Tharp TA, Traynor JR, Mosberg HI.

J Pept Res. 2005 Mar;65(3):333-42.

45.

Receptor-antagonist interactions in the complexes of agouti and agouti-related protein with human melanocortin 1 and 4 receptors.

Chai BX, Pogozheva ID, Lai YM, Li JY, Neubig RR, Mosberg HI, Gantz I.

Biochemistry. 2005 Mar 8;44(9):3418-31.

PMID:
15736952
46.

Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.

Fowler CB, Pogozheva ID, Lomize AL, LeVine H 3rd, Mosberg HI.

Biochemistry. 2004 Dec 21;43(50):15796-810.

PMID:
15595835
47.

Quantification of helix-helix binding affinities in micelles and lipid bilayers.

Lomize AL, Pogozheva ID, Mosberg HI.

Protein Sci. 2004 Oct;13(10):2600-12. Epub 2004 Aug 31.

48.

Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites.

Fowler CB, Pogozheva ID, LeVine H 3rd, Mosberg HI.

Biochemistry. 2004 Jul 13;43(27):8700-10.

PMID:
15236578
49.

Pharmacophore and receptor models for neurokinin receptors.

Poulsen A, Bjørnholm B, Gundertofte K, Pogozheva ID, Liljefors T.

J Comput Aided Mol Des. 2003 Nov;17(11):765-83.

50.

Supplemental Content

Loading ...
Support Center